. 2023 Nov 10;4(11):101279. doi: 10.1016/j.xcrm.2023.101279

Table 2.

Response and survival outcome

Endpoint	No. (%) (n = 22)
Response at the end of chemotherapy

Complete response	0 (0)
Partial response	18 (81.8)
Stable disease	3 (13.6)
Progressive disease	1 (4.5)
Objective response	18 (81.8)
Disease control	21 (95.5)

Response at the end of radiotherapy

Complete response	3 (13.6)
Partial response	16 (72.7)
Stable disease	1 (4.5)
Progressive disease	2 (9.1)
Objective response	19 (86.4)
Disease control	20 (90.9)

Response at 3 months after radiotherapy

Complete response	5 (22.7)
Partial response	13 (59.1)
Stable disease	0 (0)
Progressive disease	4 (18.2)
Objective response	18 (81.8)
Disease control	18 (81.8)

Progression-free survival

Median follow-up time, months (IQR)	30.6 (10.5–32.7)
Failures	11 (50.0)
12 months	63.6% (46.4%–87.3%)
24 months	53.8% (36.4%–79.7%)
36 months	44.9% (26.4%–76.3%)

Note: data are n (%), months (IQR), or survival estimate (95% CI), unless otherwise specified. Responses were assessed in accordance with the RECIST version 1.1.

Abbreviations are as follows: CI, confidence interval; IQR, interquartile range; RECIST, Response Evaluation Criteria in Solid Tumors.